Ignite Creation Date:
2025-12-26 @ 12:14 PM
Ignite Modification Date:
2026-01-13 @ 11:47 AM
Study NCT ID:
NCT00299000
Status:
COMPLETED
Last Update Posted:
2011-07-22
First Post:
2006-03-02
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
A Phase 4 Two Dose Level Study of Naglazyme(TM) (Galsulfase) in Infants With MPS VI
Sponsor:
BioMarin Pharmaceutical
Organization:
Organization Data
Organization:
Class:
INDUSTRY
Study ID:
ASB-008
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Lead Sponsor Class:
INDUSTRY
Responsible Party:
Responsible Party Title:
Responsible Party Type:
None
Responsible Party Affiliation:
Old Name:
Celeste Decker, MD
Old Organization:
BioMarin Pharmaceutical Inc.